Skip to main content
Signal8
Launch Terminal

Annovis Bio, Inc. (ANVS)

Annovis Bio, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for neurodegenerative disorders. The firm's flagship drug, Buntanetap, an oral medication, has successfully advanced through Phase 2a clinical trials for Alzheimer's and Parkinson's diseases. This compound is also currently being evaluated in clinical studies for Alzheimer's disease in individuals with Down Syndrome, as well as for various other chronic neurodegenerative conditions. Beyond Buntanetap, Annovis Bio is developing ANVS405 to offer protection against traumatic brain injury and stroke. Additionally, ANVS301 is progressing through Phase I clinical trials, aiming to enhance cognitive capabilities in the later stages of Alzheimer's disease and broader dementia. The company was founded in 2008 and operates out of Berwyn, Pennsylvania.

Sector: Pharmaceutical Preparations

Industry: Biotechnology

Annovis Bio, Inc. logo

Annovis Bio, Inc.

NYSE:ANVSHealthcare
+10.78%$1.13
AH$1.12-0.57%vs close
Mkt Cap$48.23M
Float37.15M
O/S42.68M
Vol
$ Vol
RVOL
Inst Own25.3%
Earnings
Dilution
Annovis Bio, Inc. logoNYSE:ANVS$1.13+10.78%
FormDescription
8-K
3.01,7.01,9.01
4
8-K
8.01,9.01
13G/A
Beneficial Ownership Report (Amended)
1
DEFA14A
Additional Proxy Materials
3
DEF 14A
Definitive Proxy Statement
6
PRE 14A
Preliminary Proxy Statement
10-Q
Quarterly Report
7
8-K
2.02,9.01
5
13G
Beneficial Ownership Report
13G
Beneficial Ownership Report
8-K
8.01,9.01
8-K
5.07,9.01
4
OWNERSHIP DOCUMENT
8-K
1.01,7.01,9.01
3
424B5
Prospectus Supplement
5
424B5
Prospectus Supplement
10-Q
Quarterly Report
4
8-K
2.02,9.01
3
DEFA14A
Additional Proxy Materials
DEF 14A
Definitive Proxy Statement
8-K
1.01,7.01,9.01
424B5
Prospectus Supplement
4
OWNERSHIP DOCUMENT
144
Notice of Proposed Sale of Securities
8-K
5.02,9.01

1-25 of 309

…

Recent SEC filings with analysis